Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus XYZAL ALLERGY 24HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus XYZAL ALLERGY 24HR.
DRIXORAL vs XYZAL ALLERGY 24HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine. It selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses such as itching, sneezing, and rhinorrhea.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
5 mg (1 tablet) orally once daily, preferably in the evening.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Terminal elimination half-life is approximately 8-9 hours in healthy adults. In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged to up to 21 hours.
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Primarily renal excretion; approximately 85% of the dose is excreted unchanged in urine, with the remainder as metabolites (mainly the conjugate) in feces via biliary elimination (~10-13%).
Category C
Category C
Antihistamine/Decongestant
Antihistamine